NATCO PHARMA LTD
GenericsNATCO PHARMA LTD is a generic drug manufacturer focused on Oncology, Neurology, Gastroenterology.
NATCO PHARMA LTD's Key Drugs
NATCO PHARMA LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NATCO PHARMA LTD's Recent FDA Approvals
NATCO PHARMA LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
NATCO PHARMA LTD's Therapeutic Areas
NATCO PHARMA LTD's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NATCO PHARMA LTD's Top Competitors
NATCO PHARMA LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Bristol-Myers Squibb, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NATCO PHARMA LTD Pipeline Snapshot
NATCO PHARMA LTD has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1987-02-09
- Latest
- 2026-06-23
- Applications
- 48